Click to goto CDHA Public Site Click to goto DivEMS Dal Public Site Click to goto EHS Nova Scotia

Pediatric Stridor

Date Last Search Run: Jun 11, 2024
Table last updated: Sep 16, 2023
Data last added: Sep 13, 2023

Recommendation RECOMMENDATION FOR INTERVENTION
STRENGTH OF EVIDENCE FOR INTERVENTION   SUPPORTIVE (Green) NEUTRAL (Yellow) AGAINST (Red) NOT YET GRADED (White)
1 (strong evidence exists)      
2 (fair evidence exists)    
3 (weak evidence exists)    


Interventions

Epinephrine-Nebulized
Level Direction Primary Outcome Patient/Process Setting Reference
II Supportive (Green) variation in RE use between ED Process ED-MD Walsh PS, Zhang Y, Lipshaw MJ. Variation in Emergency Department Use of Racemic Epinephrine and Associated Outcomes for Croup. Hosp Pediatr 2023; 13(2):167-73. Medline
III Supportive (Green) DC from ED Process ED-MD Ledwith CA., Shea LM., Mauro RD. Safety and efficacy of nebulized racemic epinephrine in conjunction with oral dexamethasone and mist in the outpatient treatment of croup. Ann Emerg Med 1995; 25(3):331-337. Medline

Hypertonic Saline-Nebulized
Level Direction Primary Outcome Patient/Process Setting Reference

Oxygen
Level Direction Primary Outcome Patient/Process Setting Reference

Oxygen-Humidified
Level Direction Primary Outcome Patient/Process Setting Reference
III Supportive (Green) Discharge from ED Process ED-MD Ledwith CA., Shea LM., Mauro RD. Safety and efficacy of nebulized racemic epinephrine in conjunction with oral dexamethasone and mist in the outpatient treatment of croup. Ann Emerg Med 1995; 25(3):331-337. Medline

Oxymetry Monitoring
Level Direction Primary Outcome Patient/Process Setting Reference

Steroids-Oral
Level Direction Primary Outcome Patient/Process Setting Reference
III Supportive (Green) DC from ED Process ED-MD Ledwith CA., Shea LM., Mauro RD. Safety and efficacy of nebulized racemic epinephrine in conjunction with oral dexamethasone and mist in the outpatient treatment of croup. Ann Emerg Med 1995; 25(3):331-337. Medline


[ PEP Database - Table of Contents ] [ Email: PEP@Dal.ca ]